Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Apr;57(4):448-55.
doi: 10.1046/j.1365-2125.2003.02030.x.

Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese

Ichiro Fukazawa  1 , Naoki Uchida, Eiji Uchida, Hajime Yasuhara
Affiliations
Clinical Trial

Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese

Ichiro Fukazawa et al. Br J Clin Pharmacol. 2004 Apr.

Abstract

Aims: To investigate the effects of repeated grapefruit juice (GFJ) intake on the pharmacokinetics of atorvastatin and pravastatin in Japanese subjects.

Methods: Two randomized, two-way crossover studies were performed. GFJ or water was given to two groups of 10 subjects each three times daily for 2 days. On the third day, single 10 mg doses of atorvastatin or pravastatin were orally administered with GFJ or water, and an additional 250 ml of GFJ or water was taken before lunch and dinner. Plasma concentrations of atorvastatin and its metabolites were determined over 48 h postdosing and of pravastatin and its metabolites over 24 h postdosing.

Results: Compared with in the water group, the AUC(0,48 h) of atorvastatin acid significantly increased by 1.40 fold (95% CI 1.02, 1.92; P < 0.05) when atorvastatin was taken with GFJ. AUC(0,48 h) and C(max) of atorvastatin lactone significantly increased by 1.56 (95% CI 1.33, 1.83; P < 0.001) and 1.29 fold (95% CI 1.09, 1.51; P < 0.01), respectively, when atorvastatin was taken with GFJ. No significant changes were detected in any pravastatin pharmacokinetic parameter examined when pravastatin was taken with GFJ. However, AUC(0,24 h) of pravastatin lactone increased 1.31 fold (95% CI 1.01, 1.71; P < 0.05) with GFJ intake.

Conclusions: GFJ was confirmed to significantly affect the pharmacokinetics of atorvastatin but had little or no effect on those of pravastatin in Japanese subjects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma concentrations (mean ± SD) of atorvastatin acid (above) and atorvastatin lactone (below) after a single 10 mg dose of atorvastatin. Water intake group (○); GFJ intake group (•)
Figure 2
Figure 2
Plasma concentrations (mean ± SD) of 2-hydroxyatorvastatin acid (above) and 2-hydroxyatorvastatin lactone (below) after a single 10 mg dose of atorvastatin. Water intake group (○); GFJ intake group (•)
Figure 3
Figure 3
Plasma concentrations (mean ± SD) of pravastatin (above) and pravastatin lactone (below) after a single 10 mg dose of pravastatin. Water intake group (○); GFJ intake group (•)
See this image and copyright information in PMC

References

    1. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: Furocoumarin dimers as components of drug interaction. Pharmacogenetics. 1997;7:391–6. - PubMed
    1. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 1998;11:252–9. - PubMed
    1. Edwards DJ, Bellevue FH, rd Woster PM. Identifition of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos. 1996;24:1287–90. - PubMed
    1. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanism of enhanced oral availability of CYP34A substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos. 1997;25:1228–33. - PubMed
    1. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice–drug interactions. Br J Clin Pharmacol. 1998;46:101–10. - PMC - PubMed

Publication types